title: Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C.
abstract: OBJECTIVE
  To evaluate serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C virus (HCV) infection.
  
  
  METHODS
  The study included 30 children with chronic HCV infection before receiving antiviral therapy. Chronic HCV infection was defined by positive anti-HCV, a positive polymerase chain reaction for HCV-RNA for more than 6 mo with absence of any associated liver disease. A second group of 30 age- and sex-matched healthy children served as controls. Serum C4a levels were measured by enzyme-linked immunosorbent assay. Liver fibrosis stage and inflammatory grade were assessed using Ishak scoring system. Serum C4a levels were compared according to different clinical, laboratory and histopathological parameters. Statistical significance for quantitative data was tested by Mann-Whitney U non-parametric tests. For qualitative data, significance between groups was tested by χ(2) test. Correlation was tested by Spearman's test. Results were considered significant if P value ≤ 0.05.
  
  
  RESULTS
  The age of the patients ranged from 3.5 to 18 years and that of controls ranged from 4 to 17 years. C4a mean levels were merely lower in patients (153.67 ± 18.69 mg/L) than that in the controls (157.25 ± 11.40 mg/L) with no statistical significance (P = 0.378). It did not differ significantly in patients with elevated vs those with normal transaminases (152.25 ± 16.62 vs 155.36 ± 21.33; P = 0.868) or with different HCV viremia (P = 0.561). Furthermore, there was no statistical significant difference in serum levels between those with no/mild fibrosis and those with moderate fibrosis (154.65 ± 20.59 vs 152.97 ± 17.72; P = 0.786) or minimal and mild activity (155.1 ± 21.93 vs 152.99 ± 17.43; P = 0.809). Though statistically not significant, C4a was highest in fibrosis score 0 (F0), decreasing in F1 and F2 to be the lowest in F3. When comparing significant fibrosis (Ishak score ≥ 3) vs other stages, C4a was significantly lower in F3 compared to other fibrosis scores (143.55 ± 2.33 mg/L vs 155.26 ± 19.64 mg/L; P = 0.047) and at a cutoff value of less than 144.01 mg/L, C4a could discriminate F3 with 76.9% sensitivity and 75% specificity from other stages of fibrosis.
  
  
  CONCLUSIONS
  Serum complement C4a did not correlate with any of transaminases, HCV viremia or with the histopathological scores. Although C4a decreased with higher stages of fibrosis, this change was not significant enough to predict individual stages of fibrosis. Yet, it could predict significant fibrosis with acceptable clinical performance.
authors.affiliation: Behairy E Behairy, Mostafa M Sira, Department of Pediatric Hepatology, National Liver Institute, Menofiya University, Shebin El-koom, Menofiya 32511, Egypt.
authors.forename: Behairy E
authors.initials: BE
authors.lastname: Behairy
authors.forename: Ghada M
authors.initials: GM
authors.lastname: El-Mashad
authors.forename: Ragab S
authors.initials: RS
authors.lastname: Abd-Elghany
authors.forename: Enas M
authors.initials: EM
authors.lastname: Ghoneim
authors.forename: Mostafa M
authors.initials: MM
authors.lastname: Sira
keywords: Children; Complement C4a; Hepatitis C virus; Liver biopsy; Liver fibrosis
references.citation: Hepatology. 2008 Mar;47(3):836-43
references.pmid: 18167062
references.citation: Mol Cell Proteomics. 2002 Nov;1(11):845-67
references.pmid: 12488461
references.citation: Hepatology. 1996 Jun;23(6):1334-40
references.pmid: 8675148
references.citation: Semin Cell Dev Biol. 1998 Jun;9(3):329-37
references.pmid: 9665870
references.citation: Eur J Pediatr. 2008 Feb;167(2):219-24
references.pmid: 17464514
references.citation: J Viral Hepat. 2009 Sep;16(9):650-8
references.pmid: 19413698
references.citation: J Gastroenterol Hepatol. 2011 May;26(5):802-9
references.pmid: 21198831
references.citation: J Pediatr Gastroenterol Nutr. 2000 Nov;31(5):536-9
references.pmid: 11144439
references.citation: Hepatology. 2003 Sep;38(3):577-88
references.pmid: 12939584
references.citation: J Exp Med. 1990 Jan 1;171(1):129-40
references.pmid: 2295875
references.citation: J Viral Hepat. 2007 Nov;14(11):788-96
references.pmid: 17927615
references.citation: J Infect. 2006 Apr;52(4):305-8
references.pmid: 16473408
references.citation: Gastroenterology. 2003 Jan;124(1):97-104
references.pmid: 12512034
references.citation: Trans R Soc Trop Med Hyg. 2008 Sep;102(9):935-8
references.pmid: 18656216
references.citation: J Immunol. 1997 Dec 15;159(12):6176-83
references.pmid: 9550420
references.citation: Clin Exp Immunol. 2007 Jan;147(1):90-8
references.pmid: 17177967
references.citation: Curr Issues Mol Biol. 2007 Jan;9(1):63-9
references.pmid: 17263146
references.citation: Clin Exp Immunol. 2002 Jan;127(1):131-6
references.pmid: 11882043
references.citation: World J Gastroenterol. 2007 Mar 28;13(12):1828-32
references.pmid: 17465475
references.citation: J Pediatr Gastroenterol Nutr. 1994 Apr;18(3):279-83
references.pmid: 8057208
references.citation: Lancet Infect Dis. 2009 Feb;9(2):108-17
references.pmid: 19179226
references.citation: J Hepatol. 1995 Jun;22(6):696-9
references.pmid: 7560864
references.citation: Turk J Gastroenterol. 2012 Feb;23(1):33-7
references.pmid: 22505377
references.citation: Mol Med Rep. 2012 Aug;6(2):259-64
references.pmid: 22614103
references.citation: PLoS One. 2013;8(1):e53519
references.pmid: 23326448
references.citation: Immunohematology. 2010;26(1):30-8
references.pmid: 20795316
references.citation: J Hepatol. 2000 Jun;32(6):911-20
references.pmid: 10898311
references.citation: J Pediatr Hematol Oncol. 2011 Apr;33(3):e92-7
references.pmid: 21317809
references.citation: J Transl Med. 2007 Jul 11;5:33
references.pmid: 17625010
references.citation: Hepatology. 2003 Aug;38(2):518-26
references.pmid: 12883497
references.citation: Dig Dis Sci. 2011 Nov;56(11):3305-15
references.pmid: 21590334